16 completed, 4 not yet recruiting, 4 recruiting, 3 active not recruiting. 31 Phase 3, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 31 | Completed 16, Not yet recruiting 4, Recruiting 4, Active not recruiting 3, Unknown 3, Withdrawn 1 |
| Phase 2 | 6 | Completed 5, Active not recruiting 1 |
Follow Pyrazinamide: new trials by email Literature Review of Pyrazinamide trials Research Report on Pyrazinamide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Optimal Treatment Duration for Radiographically Apparent, Bacteriologically Unconfirmed TB, Identified Through Active Case Finding (RADIO-TB Trial) Isoniazid (H), Rifampicin (R), Pyrazinamide (Z) - Tuberculosis (TB) | Phase 3 | Recruiting | University College, London | 784 | 2026-10-12 | 2026-10-26 |
| A 6-Month MDR-END Plus Regimen for Rifampicin-Resistant Tuberculosis MDR-END Plus regimen, Standard-of-care (SoC) treatment - Rifampicin-Resistant Tuberculosis | Phase 3 | Not yet recruiting | Seoul National University Hospital | 294 | 2026-10-01 | 2026-06-30 |
| Ultra-Short Regimen for Elderly DS-TB Bedaquiline (B), Sitafloxacin (S), Linezolid (L) - Pulmonary Tuberculosis | Phase 3 | Not yet recruiting | Shenzhen Third People's Hospital | 300 | 2025-07-25 | 2025-07-22 |
| A PAN-USR TB Multi-Center Trial Bedaquiline (B), Sitafloxacin (S), Linezolid (L) - Pulmonary Tuberculosis | Phase 3 | Recruiting | Shenzhen Third People's Hospital | 610 | 2025-06-18 | 2025-12-01 |
| Shortened Regimen for Drug-susceptible TB in Children Isoniazid, Rifampin, Pyrazinamide - Tuberculosis, Tuberculosis, Pulmonary | Phase 3 | Recruiting | Johns Hopkins University | 860 | 2025-01-15 | 2026-11-12 |
| Intensified Short Course Regimen for TBM in Adults High dose rifampicin (25mg/kg), Moxifloxacin 400mg, Aspirin 150 mg - Tuberculous Meningitis | Phase 3 | Not yet recruiting | Indian Council of Medical Research | 372 | 2024-03-01 | 2023-12-21 |
| Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis:Contezolid, Delamanid and Bedaquiline Cohort Bedaquiline, Delamanid, Contezolid - Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis | Phase 3 | Active not recruiting | Beijing Chest Hospital | 186 | 2023-12-22 | 2025-04-01 |
| Short-course Regimens for the Treatment of Pulmonary Tuberculosis Rifabutin, Delamanid, Bedaquiline - Tuberculosis, Pulmonary, Tuberculosis Infection | Phase 2 / Phase 3 | Active not recruiting | Centers for Disease Control and Prevention | 288 | 2023-11-21 | 2026-09-21 |
| Sitafloxacin-containing Regimens for Shortening Tuberculosis Treatment Sitafloxacin, SMZ/TMP, Rifampin - Tuberculosis, Pulmonary | Phase 3 | Unknown | First Affiliated Hospital of Zhejiang University | 620 | 2022-10-01 | 2022-07-12 |
| Testing New Strategies for Patients Hospitalised With HIV-associated Disseminated Tuberculosis Rifampin, Levofloxacin, Rifampicin, Pyrazinamide, Ethambutol and Isoniazid - Disseminated Tuberculosis, HIV | Phase 3 | Active not recruiting | University of Cape Town | 732 | 2021-08-11 | 2026-01-06 |
| Novel Triple-dose Tuberculosis Retreatment Regimen 6EH³R³Z, 6EHRZ - Multidrug-resistant Tuberculosis, Pulmonary Tuberculosis | Phase 3 | Recruiting | Institute of Tropical Medicine, Belgium | 370 | 2021-03-01 | 2025-04-13 |
| Treating Tuberculosis With the Lipid Lowering Drug Atorvastatin in Nigeria(ATORvastatin in Pulmonary TUBerculosis) Atorvastatin with standard anti tuberculosis drugs, Standard anti tuberculosis drugs only - Tuberculosis, Pulmonary, Tuberculosis | Phase 2 / Phase 3 | Completed | Obafemi Awolowo University Teaching Hospital | 150 | 2021-01-19 | 2023-12-08 |
| Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin (Hi-DoRi-3) High-dose rifampicin, Isoniazid, Pyrazinamide - Tuberculosis, Pulmonary | Phase 3 | Not yet recruiting | Seoul National University Hospital | 926 | 2020-09-01 | 2020-07-24 |
| Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients Pretomanid, Bedaquiline, Moxifloxacin - Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant | Phase 2 / Phase 3 | Completed | Global Alliance for TB Drug Development | 455 | 2018-07-30 | 2026-08-27 |
| Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis Rifampicin, Isoniazid, Pyrazinamide - Tuberculosis, Pulmonary | Phase 2 / Phase 3 | Completed | University College, London | 675 | 2018-03-21 | 2023-08-14 |
| Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin Delamanid, Linezolid, Levofloxacin - Tuberculosis Multi Drug Resistant Active | Phase 3 | Withdrawn | Boston University | 2017-08-01 | 2017-09-11 | |
| A Randomised Trial to Evaluate Toxicity and Efficacy of 1200mg and 1800mg Rifampicin for Pulmonary Tuberculosis Rifampicin, Isoniazid, Ethambutol - Pulmonary Tuberculosis | Phase 3 | Completed | St George's, University of London | 672 | 2017-02-01 | 2023-04-27 |
| Evaluating Newly Approved Drugs for Multidrug-resistant TB Bedaquiline, Delamanid, Clofazimine - Tuberculosis, Multidrug-Resistant, Infection, Bacterial | Phase 3 | Completed | Médecins Sans Frontières, France | 754 | 2016-12-01 | 2025-02-10 |
| The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB Regimen A locally-used WHO-approved MDR-TB regimen (2011 guideline), Moxifloxacin, Clofazimine - MDR-TB | Phase 3 | Completed | IUATLD, Inc | 588 | 2016-03-01 | 2023-09-28 |
| Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis Rifapentine, Moxifloxacin, Rifampin - Tuberculosis | Phase 3 | Completed | Centers for Disease Control and Prevention | 2516 | 2016-01-25 | 2026-08-27 |
Showing 20 of 31. Sign in to see all of them.
Tuberculosis (17) · Tuberculosis, Pulmonary (16) · Tuberculosis, Multidrug-Resistant (8) · HIV Infections (4) · Acquired Immunodeficiency Syndrome (3) · AIDS-Related Opportunistic Infections (1) · Bacterial Infections (1) · Extensively Drug-Resistant Tuberculosis (1) · Infections (1) · Latent Tuberculosis (1) · Lung Diseases (1) · Mycobacterium Infections (1) · Respiratory Tract Diseases (1) · Respiratory Tract Infections (1) · Tuberculosis, Lymph Node (1)
Global Alliance for TB Drug Development (3) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Centers for Disease Control and Prevention (2) · Seoul National University Hospital (2) · Shenzhen Third People's Hospital (2) · Tuberculosis Research Centre, India (2) · University College, London (2) · University of Cape Town (2) · All India Institute of Medical Sciences (1) · Beijing Chest Hospital (1) · Boston University (1) · First Affiliated Hospital of Zhejiang University (1) · French National Agency for Research on AIDS and Viral Hepatitis (1) · Huashan Hospital (1) · IUATLD, Inc (1)
South Africa (11) · India (9) · Uganda (9) · China (4) · Georgia (4) · Philippines (4) · Brazil (3) · Malaysia (3) · Pakistan (3) · Tanzania (3) · United States (3) · Zambia (3) · Indonesia (2) · Kenya (2) · Mozambique (2)
A K Jain, MBBS FICA (1) · Alexander Pym, MB BMRCP PhD (1) · Ali Zumla, BSc MBChB MSc PhD (1) · Amina Jindani, MD (1) · Andreas Diacon, BM MD (1) · Andrew Nunn, BSc MSc (1) · Andrew Nunn, PhD (1) · Angela Crook (1) · Anjula Bhargava, MS (1) · Arun Aggarwal, MD (1) · Ashish Rohatgi, DTCD (1) · Ashok K Singh, MD, FCCP, FCCS (1) · Aziah Mahayiddin, MD (1) · Bhanu P Singh, MD, FCCP (1) · Bolanle A Omotoso, MD (1)
PMID 36808186, PMID 17928422, PMID 19542476, PMID 19965813, PMID 21813327, PMID 22116143, PMID 23317958, PMID 23433590, PMID 24099345, PMID 24663014, PMID 25196020, PMID 26038418, PMID 26104205, PMID 26847437, PMID 26929418, PMID 29507938, PMID 29779774, PMID 30102705, PMID 30157391, PMID 30865791, PMID 31676905, PMID 31932382, PMID 34563240, PMID 34691079, PMID 35028659, PMID 35175905, PMID 35978342, PMID 36053506, PMID 36546625, PMID 37567554, PMID 37980911, PMID 37986887, PMID 38320155, PMID 38462751, PMID 38468320, PMID 38693583, PMID 38720383, PMID 38768617, PMID 39343425, PMID 39879593, PMID 40414233, PMID 40915316